|MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation through facilitating EGFR activation.|
|Jump to Full Text|
|PMID: 22457794 Owner: NLM Status: MEDLINE|
|Although it is well known that epidermal growth factor receptor (EGFR) is involved in lung cancer progression, whether EGFR contributes to lung epithelial cell transformation is less clear. Mucin 1 (MUC1 in human and Muc1 in animals), a glycoprotein component of airway mucus, is overexpressed in lung tumors; however, its role and underlying mechanisms in early stage lung carcinogenesis is still elusive. This study provides strong evidence demonstrating that EGFR and MUC1 are involved in bronchial epithelial cell transformation. Knockdown of MUC1 expression significantly reduced transformation of immortalized human bronchial epithelial cells induced by benzo[a]pyrene diol epoxide (BPDE), the active form of the cigarette smoke (CS) carcinogen benzo(a)pyrene (BaP)s. BPDE exposure robustly activated a pathway consisting of EGFR, Akt and ERK, and blocking this pathway significantly increased BPDE-induced cell death and inhibited cell transformation. Suppression of MUC1 expression resulted in EGFR destabilization and inhibition of the BPDE-induced activation of Akt and ERK and increase of cytotoxicity. These results strongly suggest an important role for EGFR in BPDE-induced transformation, and substantiate that MUC1 is involved in lung cancer development, at least partly through mediating carcinogen-induced activation of the EGFR-mediated cell survival pathway that facilitates cell transformation.|
|Xiuling Xu; Lang Bai; Wenshu Chen; Mabel T Padilla; Yushi Liu; Kwang Chul Kim; Steven A Belinsky; Yong Lin|
Related Documents :
|2929224 - Immunocytochemical demonstration of langerhans' cells in smears and pellets of exfoliat...
3487384 - Differences in marker expression among branched histiocytic cells in t-cell areas of th...
9836744 - Glabrous1 overexpression and triptychon alter the cell cycle and trichome cell fate in ...
3128914 - Interdigitating reticulum cells in the dermal infiltrate of mycosis fungoides. an ultra...
10381384 - Contribution of plus and minus end pathways to microtubule turnover.
3159564 - Ovarian immunoreactive beta-endorphin and estrous cycle in the rat.
|Type: Journal Article; Research Support, N.I.H., Extramural Date: 2012-03-22|
|Title: PloS one Volume: 7 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2012|
|Created Date: 2012-03-29 Completed Date: 2012-08-03 Revised Date: 2013-06-26|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e33846 Citation Subset: IM|
|Molecular Biology and Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico, United States of America.|
|APA/MLA Format Download EndNote Download BibTex|
Bronchi / cytology, drug effects*, metabolism
Cell Line, Transformed
Epithelial Cells / drug effects, metabolism
Extracellular Signal-Regulated MAP Kinases / metabolism
Mucin-1 / physiology*
Proto-Oncogene Proteins c-akt / metabolism
Receptor, Epidermal Growth Factor / metabolism*
|R01ES017328/ES/NIEHS NIH HHS|
|0/MUC1 protein, human; 0/Mucin-1; 55097-80-8/7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; EC 184.108.40.206/Receptor, Epidermal Growth Factor; EC 220.127.116.11/Proto-Oncogene Proteins c-akt; EC 18.104.22.168/Extracellular Signal-Regulated MAP Kinases|
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Publisher: Public Library of Science, San Francisco, USA
Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received Day: 5 Month: 1 Year: 2012
Accepted Day: 18 Month: 2 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 22 Month: 3 Year: 2012
Volume: 7 Issue: 3
E-location ID: e33846
PubMed Id: 22457794
Publisher Id: PONE-D-12-00480
|MUC1 Contributes to BPDE-Induced Human Bronchial Epithelial Cell Transformation through Facilitating EGFR Activation Alternate Title:MUC1 Facilitates HBEC Cell Transformation|
|Mabel T. Padilla1|
|Kwang Chul Kim2|
|Steven A. Belinsky1|
1Molecular Biology and Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico, United States of America
2Department of Physiology and Lung Center, Temple University School of Medicine, Philadelphia, Pennsylvania, United States of America
|Emory University, United States of America
|Correspondence: * E-mail: firstname.lastname@example.org
Contributed by footnote: Conceived and designed the experiments: Y. Lin KCK SB. Performed the experiments: XX LB WC MP. Analyzed the data: Y. Liu. Wrote the paper: XX Y. Lin.
Lung cancer is a major health concern, afflicting approximately 160,000 people each year in the United States , . Most lung cancers are associated with mainstream or sidestream cigarette smoke (CS). Carcinogens derived from CS such as benzo(a)pyrene (BaP) induce lung cancer through DNA damage. Because of activation of DNA repair pathways that remove genomic lesions and apoptosis that eliminates cells with extensive genetic damage, only a small fraction of cells acquiring DNA damage become malignant. Therefore, cancer development and progression likely depend on the balance between cell survival and apoptosis signals, both of which are activated by carcinogens and environmental factors. The pathways controlling survival include mitogen-activated protein kinases (MAPK), Akt and NF-κB , , . Although we have learned a great deal about the tumor-promoting role of survival signaling, how CS activates these pathways in lung cancer initiation and progression remains poorly understood. Thus, delineating the mechanisms underlying the influences of survival signaling on cell transformation and tumor development could identify novel intervention targets for prevention and therapy for lung cancer.
Aberrant epidermal growth factor receptor (EGFR) activation is involved in cancer progression , , . Lung cancer cells acquire dependence on EGFR activity for survival, substantiating the use of EGFR inhibitors for lung cancer therapy , . The ligands for EGFR including EGF and transforming growth factor α (TGFα) bind EGFR, triggering EGFR dimerization and autophosphorylation. The autophosphorylated C-terminal tyrosine kinase domain of EGFR in the cytoplasm initiates a cascade of intracellular signaling pathways , , , . The EGFR downstream signaling pathways include components of the Ras/Raf/MAPK (ERK, JNK and p38) and PI3K/Akt, of which ERK and Akt are two main kinases for EGFR-mediated cell survival and proliferation. The EGFR signaling is terminated by endocytosis of the phosphorylated receptor–ligand complex followed by proteasomal degradation of EGFR . How EGFR is activated by carcinogen in lung epithelial cells and whether EGFR is required for lung epithelial transformation is not well understood. In a breast cancer mouse model, mucin 1 (MUC1 for human and Muc1 for nonhuman species) facilitated TGFα-induced EGFR activation and breast cancer development , . Therefore, it is interesting to determine if MUC1 is also involved in carcinogen-induced EGFR activation for lung cancer development.
As a mucin family protein expressed on the bronchial epithelial cell membrane, MUC1 is induced during airway inflammation and plays an important role for the resolution of inflammation during respiratory tract infection , , , . During chronic inflammation, MUC1 expression is sustained at a high level, which may contribute to cancer development . MUC1 has two subunits that are coded by a single gene: the N-terminal subunit containing highly conserved repeats of 20 amino acids that are modified by O-glycosylation and the transmembrane C-terminal subunit containing 72 amino acids residues that binds to various proteins involved in signal transduction , . MUC1 is regarded as a tumor antigen because it is aberrantly overexpressed in various cancers including lung cancer, and immunotherapy with anti-MUC1 antibodies showed substantial anticancer effect against prostate and breast cancers . Although artificial overexpression of MUC1 triggers fibroblast cell transformation, the mechanism for this process is poorly understood . While MUC1 interacts with a variety of cellular factors, recent studies have suggested functional interactions between MUC1 and EGFR-mediated survival signaling , , , , . Interestingly, MUC1 expression levels were reported to be associated with response to EGFR inhibitors in lung cancer patients . In non-small cell lung cancer, MUC1 is expressed in a depolarized pattern and correlated with poor patient survival . Although it is known that MUC1 is involved in lung cancer progression particularly in metastasis and MUC1 is regarded as target for lung cancer therapy , , , , whether and how MUC1 contributes to CS-induced lung cancer initiation, particularly in lung epithelial cell transformation has not been well elucidated.
The goal of this study was to investigate the role and underlying mechanisms of MUC1 bronchial epithelial transformation. The results show that MUC1 contributes to the CS-specific carcinogen benzo(a)pyrene diol epoxide (BPDE)-induced human epithelial cell transformation through facilitating a cell survival pathway consisting of EGFR, Akt and ERK, highlighting that MUC1 and EGFR could be molecular targets for lung cancer prevention.
BPDE was obtained from NCI Chemical Carcinogen Reference Standards Repository, Midwest Research Institute. Cycloheximide was purchased from Sigma. EGFR inhibitor II (a selective and irreversible inhibitor that blocks EGFR autophosphorylation), LY294002, U0126, and SP600125 were purchased from Calbiochem. Small interfering RNA (siRNA; SiGenome SMARTpool) for MUC1, EGFR and negative control siRNA were purchased from Dharmacon. The following primary antibodies were used for Western blot: anti-Mucin 1 (GP1.4, Santa Cruz), anti-β-Tubulin and -β-Actin (Sigma-Aldrich); and anti-phospho-EGFR (Y1086, Abcam), and anti-EGFR, -ERK, -Akt and -phospho-Akt (Ser473) (Cell Signaling Technology); anti-phospho-ERK (Y185/187) (Biosource). Filters collected from the AMESA Type 1300 smoking machine, which generated mainstream CS, were used to prepare cigarette smoke extract (CSE) by sequentially extracting materials from with culture medium (for dissolving water-soluble components) and DMSO (for dissolving water-insoluble components). The water-soluble and -insoluble fractions were mixed to make the total CSE before use. Total particulate material (TPM) was determined by weighing the filter before and after extraction. The MUC1 shRNA plasmid was constructed by inserting a synthetic oligonucleotide encoding a hairpin sequence with a 19-nucleotide stem that is homologous to the target sequence of human MUC1, [gene: CCGGGATACCTACCATCCTAT], and a 9-base loop sequence into pSilencer (Oligoengine, Seattle, WA).
BEAS-2B cells were obtained from American Type Culture Collection (ATCC) (Manassas, VA). The immortalized human bronchial epithelial cells, HBEC-2, were generously provided by Drs. Shay and Minna, Southwestern Medical Center, Dallas, TX . BEAS-2B and HBEC cells were maintained in Keratinocyte serum free medium (KSFM) (Invitrogen), supplemented with 5 µg/L of human recombinant EGF and 50 mg/L of bovine pituitary extract in plates coated with fibronectin (Athena ES). The lung cancer cell lines (H23, A549, H460, H1299, H2009 and H1568) obtained from ATCC (Manassas, VA) were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1 mM of glutamine, 100 U/ml of penicillin, and 100 µg/ml of streptomycin. Monolayer cultures were incubated at 37°C in a 95% humidified atmosphere containing 5% CO2.
BEAS-2B cells were treated with BPDE (0.1 µM) every two days for a total of 3 treatments. For each treatment, the cells were exposed to BPDE for 1 h followed by incubation in fresh medium. The cells (1×104/well, 12-well plates) were then seeded in soft agar for colony formation. Colonies in the agar were photographed and counted after 2 wk incubation. HBEC-2 cells were treated similarly as that of BEAS-2B cells with CSE (10 µg/ml TPM) or BPDE (0.1 µM) weekly (1 hr each time) for 12 wk; colonies were counted after 3 wk incubation . The average number of colonies ± S.D. was determined using 6 randomly selected fields. All experiments were run in triplicate.
BEAS-2B cells were seeded in a 6-well plate at ∼50% confluency. After overnight culture, cells were transfected with small interfering RNA (siRNA) with INTERFERin™ siRNA transfection reagent (Polyplus-transfection) according to manufacturer's instructions. Forty-eight hours after transfection, MUC-1, EGFR, Akt and ERK protein levels were determined by Western blot. For stable shRNA transfection, cells were transfected with MUC1 shRNA at 30∼50% confluency using FuGENE HD transfection reagent (Roche) following the manufacturer's instructions. Clones stably expressing MUC1 knockdown were selected with puromycin (1 µg/ml) and identified by Western blot.
Cells were harvested and total cell protein was extracted in M2 buffer (20 mM Tris-HCl, pH 7.6, 0.5% Nonidet P-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM-glycerophosphate, 1 mM sodium vanadate, and 1 µg/ml leupeptin). Equal amounts of cell proteins were resolved in 12% SDS-polyacrylamide gels and then transferred to PVDF membranes. The proteins were visualized by enhanced chemiluminescent detection reagent according to the manufacturer's instructions (Millipore).
Cytotoxicity was assessed using a 3-(4,5-dimethylthiazolyl-2-)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay and a lactate dehydrogenase (LDH) release-base cytotoxicity detection kit (Promega) . Cells were seeded in 48-well plates at ∼70% confluency, cultured overnight, and then treated as indicated in the figure legends. Cell viability was determined using MTT assay. The percentage of viable cells was calculated using the following formula: Cell viability (%) = (Absorbance of treated sample/Absorbance of control) ×100. Cell death based on the release of LDH was calculated as follows: Cell death (%) = [(Experimental value-Spontaneous LDH release)/(Maximum LDH-Spontaneous LDH release)] ×100 .
All data were expressed as mean ± S.D. Statistical significance was examined by one-way analysis of variance. In all analyses, p<0.05 was considered statistically significant.
Cell transformation, the transition of normal to cancerous cells, is a critical early process for cancer initiation. To investigate if MUC1 plays a role in bronchial epithelial cell transformation, MUC1 was knocked down by RNA interference in BEAS-2B, an immortalized human bronchial epithelial cell line that is sensitive to carcinogen-induced transformation in vitro. The cells were treated with BPDE (0.1 µM) for 1 wk and then plated in soft agar for colony formation. Remarkably, transient knockdown of MUC1 expression strikingly reduced BPDE-induced colony formation. The negative control siRNA did not affect on BPDE-induced transformation (Figs. 1A, 1B). To exclude potential off-target effect of siRNA, this observation was validated by stably knocking down MUC1 expression in BEAS-2B cells with a MUC1 shRNA targeting different site in the MUC1 messenger RNA. A dramatic reduction of BPDE-induced colony formation was seen in cells transfected with MUC1 shRNA, but not the negative shRNA (Figs. S1). These results suggest that MUC1 plays a significant role in promoting BPDE-induced bronchial epithelial cell transformation.
To investigate the underlying mechanism by which MUC1 potentiates BPDE-induced bronchial epithelial cell transformation, we focused on the activation of the EGFR pathway because this pathway can be activated by benzo(a)pyrene and MUC1 was reported to modulate EGFR activation in breast epithelial cells , . HBEC-2 and BEAS-2B cells were treated with BPDE for 2 h and activation of EGFR was detected with an antibody recognizing EGFR phosphorylated at tyrosine 1068. BPDE activated EGFR in a dose-dependent manner, starting at a concentration of 0.05 µM (Fig. 2A). Akt and ERK, two major downstream kinases of EGFR, were activated by BPDE in a similar manner (Fig. 2A). Supporting this observation, cigarette smoke extract (CSE) activated EGFR, Akt and ERK in HBEC-2, starting 15 min and persisting over 2 h after treatment (Fig. S2A). Because Akt and ERK are activated by a variety of pathways other than EGFR, we examined if BPDE-induced Akt and ERK activation is mediated by EGFR by knocking down the expression of EGFR with EGFR siRNA. While the negative control siRNA had a marginal effect on BPDE-induced activation of Akt and ERK, the EGFR siRNA, which effectively eliminated EGFR expression, completely blocked BPDE-induced Akt and ERK activation (Fig. 2B). Consistently, the EGFR inhibitor, which effectively suppressed BPDE-induced EGFR activation, effectively attenuated BPDE-induced Akt and ERK activation (Fig. 2C). Neither EGFR siRNA nor the EGFR inhibitor inhibited the expression of MUC1 (Figs. 2B, 2C), suggesting that it is unlikely that MUC1 functions downstream of EGFR for BPDE-induced Akt and ERK activation. Altogether, these results strongly suggest that BPDE activates EGFR, which in turn, mediates activation of Akt and ERK pathways in bronchial epithelial cells.
Because transformation of HBEC-2 is a slow process that takes up to 12 wk , , we then examined if chronic exposure to a non-cytotoxic concentration of BPDE that induces transformation results in EGFR activation. Cells were treated weekly with BPDE (0.1 µM) for up to 12 wk and activation of EGFR, Akt and ERK was detected by Western blot. Activation of EGFR was first detected 4 wk post treatment, gradually increased and peaked after 8 wk and was sustained at 12 wk (Fig. 3A). A similar trend of activation of Akt and ERK was also observed. EGFR, Akt and ERK activation was detected in the cells after several passages, suggesting a sustained constitutive activation of EGFR-mediated pathways. Interestingly, the expression level of MUC1 is also induced at 4 wk and gradually increased through 12 wk (Fig. 3A). Consistent with the results from BPDE treatment, chronic CSE exposure similarly activated EGFR, Akt and ERK activation, which was also associated with increased MUC1 expression (Fig. S2B). These results suggest that chronic exposure to BPDE results in constitutive activation of EGFR, Akt, and ERK, which is associated with increased expression of MUC1 in HBEC-2 cells. To further substantiate the finding that EGFR is activated during transformation, we examined this pathway in precancerous cells HBEC-2B, which were derived from colonies that formed in soft agar after chronic BPDE exposure , . Although these cells were unable to form tumors in nude mice , , they readily form colonies in soft agar (Fig. 3B). In these cells, EGFR, Akt and ERK were constitutively activated in association with MUC1 overexpression (Fig. 3C). The association of MUC1 expression and EGFR activation suggests that MUC1 plays a role in BPDE-induced EGFR activation and cell transformation.
Because survival of cells with genetic mutations is essential for cancer initiation and Akt and ERK are well known survival signals, we next investigated if BPDE-induced and EGFR-mediated Akt and ERK activation protects cells from BPDE-induced cytotoxicity. Pharmacological inhibitors blocking each pathway were followed by treatment with BPDE at a concentration (0.2 µM) that induced moderate cell death. Under this condition, BPDE caused ∼20% cell death that was detected by LDH release and MTT assays. While the EGFR inhibitor alone was slightly toxic, it dramatically increased cell death. Coordinately, the PI3 kinase (PI3K)/Akt inhibitor LY294002 effectively potentiated BPDE-induced cytotoxicity. Surprisingly, the MEK/ERK inhibitor U0126 had only a slight sensitization to BPDE-induced cell death. As a control, the JNK inhibitor SP600125 had little effect on BPDE's cytotoxicity (Fig. 4A, 4B). All the inhibitors were effective in blocking their respective pathways (data not shown) . These results suggest EGFR-mediated pathways, particularly Akt, play important roles in protecting bronchial epithelial cells against BPDE-induced cell death, which may contribute to lung cancer development.
Next, we assessed the role of EGFR, Akt and ERK in BPDE-induced cellular transformation. BEAS-2B cells were treated with BPDE (0.1 µM), with or without inhibitors against each pathway for 1 wk, and then plated in soft agar for colonies formation. As expected, inhibition of EGFR and Akt effectively suppressed BPDE-induced colonies formation. Surprisingly, the ERK inhibitor U0126, which only slightly increased BPDE's cytotoxicity, effectively blocked BPDE-induced transformation (Fig. 5A, 5B). This observation suggests that ERK contributes to cell transformation by a mechanism other than cell survival. Nevertheless, these results suggest that activation of EGFR, Akt and ERK is required for transforming human bronchial epithelial cells.
Because BPDE stimulated EGFR-mediated Akt and ERK activation that was associated with MUC1 overexpression (Figs. 3A, 3C) and MUC1 modulates EGFR activation in breast epithelial cells , , we examined if MUC1 is involved in BPDE-induced activation of EGFR-mediated Akt and ERK pathways. BEAS-2B cells with stable MUC1 knockdown were compared to the cells stably transfected with a negative shRNA vector with respect to BPDE-induced EGFR, Akt and ERK activation. Although the phosphorylation of EGFR, Akt and ERK was substantially activated by BPDE in the control cells, MUC1 knockdown completely attenuated BPDE-induced activation of these pathways (Fig. 6A). These results strongly suggest that MUC1 is required for BPDE-induced activation of EGFR, Akt and ERK in bronchial epithelial cells. It is worthy noting that the basal pERK was remarkably higher in the MUC1 knockdown cells and the extent of suppression of BPDE-induced ERK activation was lower than that of Akt. This may be explained by the complexity of ERK activation in cells and other pathway(s) may compensate the suppression of EGFR-mediated ERK activation.
It was noticed that the expression of EGFR protein was reduced in the MUC1 knockdown cells (Fig. 6A). However, the EGFR message RNA expression levels were comparable between the cells with or without MUC1 knockdown (Fig. 6B). Therefore, we examined if the stability of EGFR is regulated by MUC1. Protein synthesis was shut off with cycloheximide and MUC1 expression was monitored for up to 3 hr. The half-life of EGFR in the MUC1-suppressed cells was ∼32 min, much shorter than that of the negative control shRNA transfected cells (∼145 min) (Fig. 6B). The mechanism of EGFR degradation is complex, which involves a pathway involving both lysosome and proteasome . Consistently, the proteasome inhibitor MG132 and lysosome inhibitor chloroquine alone or in combination eliminated the EGFR expression difference between the MUC1 knockdown and control cells (Fig. S3). These results imply that decreased EGFR protein stability contributes to decreases of this protein expression in MUC1-suppressed cells, which leads to the suppression of BPDE-induced activation of EGFR, Akt and ERK.
Having established that MUC1 is required for BPDE-induced activation of EGFR-mediated Akt and ERK that protects bronchial epithelial cells against BPDE's cytotoxicity, we further investigated if MUC1 plays a survival role when cells are exposed to BPDE. BEAS-2B cells with stable MUC1 knockdown and control cells transfected with negative shRNA were treated with different concentrations of BPDE and cytotoxicity was detected by LDH release and MTT assays. The results clearly show that knockdown of MUC1 substantially potentiated BPDE-induced cell death (Fig. 6C). Because in the MUC1 knockdown cells BPDE-induced activation of EGFR-mediated Akt and ERK is suppressed (Fig. 6A) and these pathways are required for cell survival during BPDE challenge and BPDE induced transformation (Figs. 4, 5), it is likely that MUC1 protects the cells from BPDE-induced cytotoxicity and promotes cell transformation through potentiating BPDE-induced activation of EGFR-mediated survival pathways.
This study provides strong evidence supporting a cancer-promoting role of MUC1 in CS-induced lung carcinogenesis: MUC1 potentiated transformation of human bronchial cells induced by the tobacco carcinogen BPDE; BPDE markedly activated EGFR and its downstream pathways Akt and ERK, and blocking these pathways significantly increased BPDE-induced cytotoxicity and inhibited cell transformation; Suppression of MUC1 expression destabilized EGFR protein and inhibited BPDE-induced activation of EGFR, Akt and ERK, and subsequently increased BPDE-induced cell death. These results suggest that BPDE-induced transformation requires EGFR-mediated Akt and ERK activation, and that MUC1 plays a lung cancer-promoting role during lung cancer development, at least partly through mediating carcinogen-induced activation of the EGFR-mediated cell survival pathways that neutralize carcinogen's cytotoxicity to facilitate cell transformation (Fig. 7).
Although the role of EGFR in lung cancer progression is well known, whether and how EGFR contributes to lung epithelial cell transformation is less clear. Specifically, whether EGFR is involved in CS-induced transformation of lung epithelial cells has not been reported. We found that CSE or the tobacco specific carcinogen BPDE activate EGFR, and blocking EGFR signaling effectively suppressed BPDE-induced transformation. These results clearly place EGFR as a pivotal factor for lung cancer development at the early time point. Our results further demonstrate that the EGFR-mediated signaling pathways, particularly Akt, prevent cells from BPDE's cytotoxic effect and thereby potentiate bronchial epithelial cell transformation. The ERK pathway, which contributed moderately to cell survival, significantly potentiated cell transformation presumably through a mechanism other than cell survival. In addition to cell survival, ERK is a major pathway for cell proliferation . Indeed, proliferation of mutated cells after acquiring genetic and epigenetic modifications for malignant transformation is vital for giving rise to tumors. Therefore, it remains to be determined if ERK potentiates cell transformation through stimulating transformed cell proliferation. Nevertheless, our results suggest that activation of EGFR is a requisite for tobacco carcinogens such as BPDE to induce malignant transformation.
Although it is known that CS activates EGFR in lung epithelial cells, the underlying mechanism is not well elucidated. It has been shown that hydrogen peroxide-mediated stabilization of EGFR is involved . Here we show evidence that EGFR is activated by CS specific carcinogen BPDE and MUC1 is required for the activation. CS-induced MUC1 distribution is related to EGFR activation in human bronchial epithelial cells . Because EGFR mRNA level was not affected by the expression of MUC1, it is unlikely that MUC1 impacts EGFR at the level of transcription. Instead, posttranslational modulation of EGFR is likely involved. Indeed, reduced EGFR protein expression was observed in the MUC1 knockdown cells. We clearly show that the stability of EGFR protein is reduced in MUC1 knockdown cells, suggesting that MUC1 potentiates BPDE-induced EGFR activation through stabilization of the latter, similarly as in ligand-induced EGFR activation in breast cancer cells . Furthermore, although we have not detected obvious induction of EGF or TGFα autocrine from bronchial epithelial cells by BPDE (data not shown), whether other EGFR ligands are involved in BPDE-induced and MUC1-potentiated EGFR activation deserves further study.
It is well known that MUC1 expression in bronchial epithelial cells is induced during inflammation , and chronic inflammation is associated with CS-induced lung carcinogenesis , . Therefore, it is plausible to hypothesize that persistent MUC1 expression during CS-induced chronic inflammation promotes lung carcinogenesis. As MUC1 potentiates BPDE-induced activation of EGFR, it is likely that MUC1 contributes to lung cancer development at least in part through EGFR-mediated cell survival pathways such as Akt and ERK. While TNFα plays an important role in inducing MUC1 expression in human lung epithelial cells during acute inflammation as well as in lung infection , , how chronic inflammation enhances MUC1 expression has not been determined. It is possible that consistent stimulation by TNFα secreted from inflammatory cells keeps MUC1 expression in bronchial and alveolar cells at high levels to promote lung cancer development , . However, other mechanisms might underlie. Indeed, in our in vitro assays with HBEC alone, MUC1 expression was induced by BPDE or CSE. MUC1 retained at a high level when cells were transformed, consistent with that MUC1 is constitutively overexpressed in lung cancers. Thus, the mechanisms by which MUC1 expression is activated by carcinogens and retained at high levels in transformed cells deserve further investigation. Nevertheless, our results suggest that MUC1 functions as a mediator that bridges CS-induced pulmonary inflammation and lung cancer development by potentiating EGFR-mediated survival signaling.
Eliminating transformed cells at the early stage of tumor initiation would be a good chemoprevention approach against cancer. In this regard, MUC1 and EGFR may serve as molecular targets for lung cancer prevention. It has been shown that targeting EGFR is able to reduce lung cancer burden in animal studies . Although targeting MUC1 and EGFR individually have been proven to be effective in treating a portion of lung cancer patients, chemoprevention against these two factors has not been studied. In addition, because combined chemoprevention targeting more than one oncogenic protein could potentiate the cancer preventive activity and reduce toxicity, it would be interesting to determine if a regime targeting both MUC1 and EGFR achieves more effective prevention against lung cancer.
Stable knockdown of MUC1 inhibits BPDE-induced transformation in BEAS-2B cells. BEAS-2B cells were infected with MUC1 shRNA or negative control shRNA and stable clones were selected. Cell transformation and data analysis are the same as described in Fig. 1 A and B. Insert, Confirmation of MUC1 knockdown by Western blot.
Click here for additional data file (pone.0033846.s001.png)
Induction of MUC1 expression and EGFR-, Akt- and ERK-activation in HBEC-2 cells by CSE exposure.A, HBEC-2 cells were treated with CSE (10 µg/ml TPM) for the indicated time periods. Activation of each protein was detected with antibodies against the phosphorylated form of the proteins. The phosphorylation sites of each protein were indicated. Total EGFR was also detected. β-Actin was detected as a loading control. B, HBEC-2 cells were treated with CSE (10 µg/ml TPM) for the indicated weeks. Western blot was same as in A. The expression of MUC1was also detected. β-Actin was detected as a loading control.
Click here for additional data file (pone.0033846.s002.png)
Blocking protein degradation with MG132 and chloroquine eliminates EGFR expression difference between the MUC1 knockdown and control cells. Beas-2B cells stably transfected with MUC1 shRNA or negative control (NC) shRNA were treated with lysosome inhibitor chloroquine (CQ, 20 µM), proteasome inhibitor MG132 (10 µM), or both for 15 h. EGFR protein was detected by Western blot. β-Actin was detected as an input control.
Click here for additional data file (pone.0033846.s003.png)
Competing Interests: The authors have declared that no competing interests exist.
Funding: This study was supported by a grant from NIEHS/NIH (R01ES017328). http://www.niehs.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
|1.||Jemal A,Siegel R,Xu J,Ward E. Year: 2010Cancer statistics, 2010.CA Cancer J Clin6027730020610543|
|2.||Wingo PA,Cardinez CJ,Landis SH,Greenlee RT,Ries LA,et al. Year: 2003Long-term trends in cancer mortality in the United States, 1930–1998.Cancer973133327512784323|
|3.||Hanahan D,Weinberg RA. Year: 2011Hallmarks of cancer: the next generation.Cell14464667421376230|
|4.||McKenzie S,Kyprianou N. Year: 2006Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.J Cell Biochem97183216216007|
|5.||Lin Y,Bai L,Chen W,Xu S. Year: 2010The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.Expert Opin Ther Targets14455520001209|
|6.||Arteaga CL. Year: 2006EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.Cancer Cell942142316766261|
|7.||Yatabe Y,Takahashi T,Mitsudomi T. Year: 2008Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.Cancer Res682106211118381415|
|8.||Zandi R,Larsen AB,Andersen P,Stockhausen MT,Poulsen HS. Year: 2007Mechanisms for oncogenic activation of the epidermal growth factor receptor.Cell Signal192013202317681753|
|9.||Wheatley-Price P,Shepherd FA. Year: 2008Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.Curr Opin Oncol2016217518300766|
|10.||Pirker R,Filipits M. Year: 2009Targeted therapies in lung cancer.Curr Pharm Des1518820619149612|
|11.||Wells A. Year: 1999EGF receptor.Int J Biochem Cell Biol3163764310404636|
|12.||Yarden Y. Year: 2001The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.Eur J Cancer37Suppl 4S3811597398|
|13.||Cohen RB. Year: 2003Epidermal growth factor receptor as a therapeutic target in colorectal cancer.Clin Colorectal Cancer224625112620146|
|14.||Li X,Wang L,Nunes DP,Troxler RF,Offner GD. Year: 2005Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor.Cancer Biol Ther496897316082192|
|15.||Pochampalli MR,Bitler BG,Schroeder JA. Year: 2007Transforming growth factor alpha dependent cancer progression is modulated by Muc1.Cancer Res676591659817638868|
|16.||Baldus SE,Engelmann K,Hanisch FG. Year: 2004MUC1 and the MUCs: a family of human mucins with impact in cancer biology.Crit Rev Clin Lab Sci4118923115270554|
|17.||Lu W,Hisatsune A,Koga T,Kato K,Kuwahara I,et al. Year: 2006Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice.J Immunol1763890389416547220|
|18.||Guang W,Ding H,Czinn SJ,Kim KC,Blanchard TG,et al. Year: 2010Muc1 cell surface mucin attenuates epithelial inflammation in response to a common mucosal pathogen.J Biol Chem285205472055720430889|
|19.||Kim KC,Lillehoj EP. Year: 2008MUC1 mucin: a peacemaker in the lung.Am J Respir Cell Mol Biol3964464718617677|
|20.||Hattrup CL,Gendler SJ. Year: 2008Structure and function of the cell surface (tethered) mucins.Annu Rev Physiol7043145717850209|
|21.||Kufe DV. Year: 2008Targeting the human MUC1 oncoprotein: A tale of two proteins.Cancer Biol Ther7|
|22.||Li Y,Liu D,Chen D,Kharbanda S,Kufe D. Year: 2003Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.Oncogene226107611012955090|
|23.||Pochampalli MR,el Bejjani RM,Schroeder JA. Year: 2007MUC1 is a novel regulator of ErbB1 receptor trafficking.Oncogene261693170116983337|
|24.||Li Y,Ren J,Yu W,Li Q,Kuwahara H,et al. Year: 2001The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.J Biol Chem276352393524211483589|
|25.||Bearz A,Talamini R,Vaccher E,Spina M,Simonelli C,et al. Year: 2007MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients.Int J Biol Markers2230731118161663|
|26.||Guddo F,Giatromanolaki A,Koukourakis MI,Reina C,Vignola AM,et al. Year: 1998MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.J Clin Pathol516676719930070|
|27.||Spicer AP,Rowse GJ,Lidner TK,Gendler SJ. Year: 1995Delayed mammary tumor progression in Muc-1 null mice.J Biol Chem27030093301018530414|
|28.||Raina D,Kosugi M,Ahmad R,Panchamoorthy G,Rajabi H,et al. Year: 2011Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells.Mol Cancer Ther1080681621421804|
|29.||Ramirez RD,Sheridan S,Girard L,Sato M,Kim Y,et al. Year: 2004Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.Cancer Res649027903415604268|
|30.||Damiani LA,Yingling CM,Leng S,Romo PE,Nakamura J,et al. Year: 2008Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells.Cancer Res689005901418974146|
|31.||Chen W,Wang X,Zhuang J,Zhang L,Lin Y. Year: 2007Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells.Carcinogenesis282114212117548900|
|32.||Wang X,Chen W,Zeng W,Bai L,Tesfaigzi Y,et al. Year: 2008Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.Mol Cancer Ther71156116318483303|
|33.||Puppala D,Gairola CG,Swanson HI. Year: 2007Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation.Carcinogenesis2863964717012224|
|34.||Burdick AD,Davis JW 2nd,Liu KJ,Hudson LG,Shi H,et al. Year: 2003Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells.Cancer Res637825783314633709|
|35.||Bitler BG,Goverdhan A,Schroeder JA. Year: 2010MUC1 regulates nuclear localization and function of the epidermal growth factor receptor.J Cell Sci1231716172320406885|
|36.||Tellez CS,Juri DE,Do K,Bernauer AM,Thomas CL,et al. Year: 2011EMT and Stem Cell-Like Properties Associated with miR-205 and miR-200 Epigenetic Silencing Are Early Manifestations during Carcinogen-Induced Transformation of Human Lung Epithelial Cells.Cancer Res713087309721363915|
|37.||Li Z,Xu X,Bai L,Chen W,Lin Y. Year: 2011Epidermal Growth Factor Receptor-mediated Tissue Transglutaminase Overexpression Couples Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance and Migration through c-FLIP and MMP-9 Proteins in Lung Cancer Cells.J Biol Chem286211642117221525012|
|38.||Alwan HA,van Zoelen EJ,van Leeuwen JE. Year: 2003Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination.J Biol Chem278357813579012829707|
|39.||Mebratu Y,Tesfaigzi Y. Year: 2009How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?Cell Cycle81168117519282669|
|40.||Goldkorn T,Filosto S. Year: 2010Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke.Am J Respir Cell Mol Biol4325926820525802|
|41.||Chen YT,Gallup M,Nikulina K,Lazarev S,Zlock L,et al. Year: 2010Cigarette smoke induces epidermal growth factor receptor-dependent redistribution of apical MUC1 and junctional beta-catenin in polarized human airway epithelial cells.Am J Pathol1771255126420651243|
|42.||Takahashi H,Ogata H,Nishigaki R,Broide DH,Karin M. Year: 2010Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.Cancer Cell17899720129250|
|43.||Lin WW,Karin M. Year: 2007A cytokine-mediated link between innate immunity, inflammation, and cancer.J Clin Invest1171175118317476347|
|44.||Koga T,Kuwahara I,Lillehoj EP,Lu W,Miyata T,et al. Year: 2007TNF-alpha induces MUC1 gene transcription in lung epithelial cells: its signaling pathway and biological implication.Am J Physiol Lung Cell Mol Physiol293L69370117575006|
|45.||Choi S,Park YS,Koga T,Treloar A,Kim KC. Year: 2011TNF-alpha is a key regulator of MUC1, an anti-inflammatory molecule, during airway Pseudomonas aeruginosa infection.Am J Respir Cell Mol Biol4425526020448050|
|46.||Wang X,Lin Y. Year: 2008Tumor necrosis factor and cancer, buddies or foes?Acta Pharmacol Sin291275128818954521|
|47.||Aggarwal BB. Year: 2003Signalling pathways of the TNF superfamily: a double-edged sword.Nat Rev Immunol374575612949498|
|48.||Kishino D,Kiura K,Takigawa N,Katayama H,Kuyama S,et al. Year: 2009Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.Lung Cancer6528428919152984|
Previous Document: Integration of subthreshold and suprathreshold excitatory barrages along the somatodendritic axis of...
Next Document: Low-dose Cd induces hepatic gene hypermethylation, along with the persistent reduction of cell death...